In the BC disease group, NanoPoms prepared exosomes enabled much enhanced detection sensitivity and specificity to BC relevant mutations including KRAS, PIK3CA, and ERBB2, which only consumed 1 mL urine sample with about 10-50 ng exosome DNAs. This evidence concerns the gene KRAS and breast cancer.